Skip to main content
LC

Linda Cardozo

🏥 King's College Hospital, London, UK
Mentored by · fellowship 1978
Stuart Stanton
Trainees (40)
Eboo Versi · 1985Andrew Tapp · 1987Christian Barnick · 1989Christopher Benness · 1990Alfred Cutner · 1991Gilbert Burton · 1991Brian Wise · 1992Cornelius Kelleher · 1994Vikram Khullar · 1994Simon Hill · 1995Carmel Ramage · 1996Stavros Athanasiou · 1996Philip Toozs-Hobson · 1997Alex Yip · 1998Kelvin Boos · 1998Andrew Hextall · 1999John Bidmead · 2000Katie Clifford · 2000Dudley Robinson · 2002Jane Rufford · 2002Piet Hinoul · 2002James Bamforth · 2004Matthew Parsons · 2005Sushma Srikrishna · 2006Arther Tseng · 2007Maria Vella · 2007Luigi Erricello · 2008 Rufus Cartwright · 2008Arasee Rangenathan · 2009Marco Torella · 2009Guy Mozogo · 2010Heleni Mastoroudes · 2010Ilias Giarenas · 2010Ismaiel Abu-Mahfouz · 2010Monika Vij · 2010Isabelle Freilling · 2011Ki Hoon Ahn · 2012Ganesh Thiagamoorthy · 2013Lanka Abeywickrama · 2013Maria Grazia Matarazzo · 2013

Biography​

Linda Cardozo (1950–2023) was professor of urogynecology and consultant gynecologist at King's College Hospital in London.12 She graduated from Liverpool University Medical School with an MBChB in 1974.3 She began a two-year research fellowship with Stuart Stanton at St. George's Hospital in 1976.2 She was president of the International Urogynecological Association from 1998 to 2000.1

Contributions​

Her confirmed cited work on clinical measurement includes validation of the P-QOL and PGI-I instruments for prolapse and an International Continence Society report on lower urinary tract terminology.456

Cited on WARWIKI

5 publications with Linda Cardozo as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–128. doi
  2. Madersbacher H, Cardozo L, Chapple C, et al. "What are the causes and consequences of bladder overdistension? ICI-RS 2011." Neurourol Urodyn. 2012;31(3):317–321. doi
  3. Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010;21(5):523-528. doi
  4. Digesu GA, Khullar V, Cardozo L, Robinson D, Salvatore S. P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(3):176-181. doi
  5. Abrams P, Cardozo L, Fall M, et al. "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society." Neurourol Urodyn. 2002;21(2):167-178. doi

Footnotes​

  1. Professor Linda Cardozo OBE. King s College Hospital NHS Foundation Trust. Accessed October 2026. ↩ ↩2

  2. The British Society of Urogynaecology (BSUG). Accessed October 2026. ↩ ↩2

  3. ICS. Prof Linda Cardozo. Accessed October 2026. ↩

  4. Digesu GA, Khullar V, Cardozo L, Robinson D, Salvatore S. P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(3):176-181. doi:10.1007/s00192-004-1225-x ↩

  5. Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010;21(5):523-528. doi:10.1007/s00192-009-1069-5 ↩

  6. Abrams P, Cardozo L, Fall M, et al. "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society." Neurourol Urodyn. 2002;21(2):167-178. doi:10.1002/nau.10052 ↩